Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03073148 · ClinicalTrials.gov registry record · NA
Evaluation of Tangible Boost Replenishing System
A NA study of Contact Lens Solution, sponsored by Tangible Science.
- Completed
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03073148: Completed NA study of Contact Lens Solution, sponsored by Tangible Science.
NCT03073148 is a NA study of Contact Lens Solution that has completed, run by Tangible Science. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03073148, a NA study of Contact Lens Solution, has completed, sponsored by Tangible Science.
- COMPLETED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate Tangible Boost, a new contact lens care product which is designed to replenish the hydrogel layer on fluorosilicone acrylate lenses with Hydra-PEG. The Hydra-PEG coating is a poly(ethylene glycol)-based hydrogel that is covalently bound to the lens surface. This coating improves lens wettability, a common cause of patient discomfort. Tangible Boost is designed to maintain the wettability of Hydra-PEG lenses throughout the lens lifetime. Patients can use the Tangible Boost kit to reapply the Hydra-PEG coating each month at home.
Primary Outcome
A report of any adverse events or discontinuations that may have occurred. This measure includes adverse events unrelated to the treatment. See adverse events section for additional details.
Conditions Studied
Interventions
- DEVICE Tangible Boost
- OTHER Placebo saline
Study Locations (1)
Texas
- University of Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2019-02-13 |
| Phase | NA |
What the finished NCT03073148 record still lists
NCT03073148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Contact Lens Solution appearing as the primary indexed condition, and to 2 interventions - of which Tangible Boost is the first listed.
NCT03073148 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03073148 about?
NCT03073148 is a clinical study titled "Evaluation of Tangible Boost Replenishing System". This study will evaluate Tangible Boost, a new contact lens care product which is designed to replenish the hydrogel layer on fluorosilicone acrylate lenses with Hydra-PEG. The Hydra-PEG coating is a poly(ethylene glycol)-based hydrogel that is covalently bound to the lens surface. This coating impr...
What is the current status of trial NCT03073148?
This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2017-02-24. Estimated completion is 2019-02-13.
What conditions does trial NCT03073148 study?
This clinical trial studies the following conditions: Contact Lens Solution.
What interventions are being tested in trial NCT03073148?
The interventions under investigation include: Tangible Boost (DEVICE), Placebo saline (OTHER).
Who is sponsoring clinical trial NCT03073148?
This trial is sponsored by Tangible Science, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03073148 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03073148's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI